At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 545 enrolled
Drug / intervention
CHS-1420 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating CHS-1420 and Adalimumab for Plaque Psoriasis. Completed, enrolled 545 participants across 99 sites in 16 countries.
Detailed Summary
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesBulgaria, Canada, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Poland, Russia, Slovakia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionMay 2016
Study CompletionMar 2017
TodayJul 2026
First PostedJul 2, 2015
Enrollment StartAug 1, 2015
Primary CompletionMay 6, 2016
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11 years ago
Interventions
CHS-1420drug
Adalimumabdrug